On 22 March, the Cybersecurity Administration of China (CAC) released the final version of a regulation governing the overseas transfer of personal, business and other data, including of health and medical data with implications for the biopharma industry.
The regulation, which takes effect immediately, sets thresholds for when companies have to file for such transfers - at one million cases of personal data or 10,000 of "sensitive" personal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?